Skip to main content

Conference Correspondent 

A large observational study showed increased first-line bendamustine-rituximab use among older patients with splenic or nodal marginal zone lymphoma was not associated with significant event-free survival or overall survival benefit versus single-agent rituximab, but led to increased toxicities and costs. Read More ›

Updated results from a phase 1/2 trial indicate that acalabrutinib monotherapy was associated with a favorable safety profile and showed antileukemic activity in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, irrespective of high-risk genomic features. Read More ›

The results of this phase 3 study demonstrate a progression-free survival advantage for patients treated with acalabrutinib given alone or in combination with obinutuzumab versus those treated with obinutuzumab plus chlorambucil. Read More ›

Use of a time-limited triplet combination of acalabrutinib, venetoclax, and obinutuzumab in patients with chronic lymphocytic leukemia offers high rates of undetectable minimal residual disease in bone marrow with acceptable tolerability. Read More ›

For patients with chronic lymphocytic leukemia who are treated with acalabrutinib, disease progression is largely attributed to specific mutations in Bruton tyrosine kinase (BTK). Acalabrutinib resistance mechanisms are similar to those seen with ibrutinib. Read More ›

In the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE study, first-line ibrutinib + venetoclax treatment resulted in high rates of undetectable MRD in both peripheral blood and bone marrow of patients with chronic lymphocytic leukemia (CLL). Read More ›

The ongoing phase 1/2 HOVON 124/Ecwm-R2 trial showed the combination of ixazomib citrate, rituximab, and dexamethasone to be feasible, with promising efficacy and manageable toxicity in patients with relapsed or progressive Waldenström macroglobulinemia. Read More ›

Extended follow-up of the E1912 trial showed a significant advantage for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib + rituximab compared with those treated with fludarabine, cyclophosphamide, and rituximab (FCR). Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

Page 11 of 28